MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Price Stock Quantity  
USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-2206 2HCl Chemical Structure

MK-2206 2HCl Chemical Structure
Molecular Weight: 480.39

Validation & Quality Control

Product Use Citation(169)

Customer Product Validation(18)

Quality Control & MSDS

Related Compound Libraries

MK-2206 2HCl is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Targets Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
IC50 8 nM 12 nM 65 nM
In vitro MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H292NIW2bllEgXSxdH;4bYMhSXO|YYm=NG\G[Fg{KM7:TR?=NX7ifI9PPzJiaB?=NHX1XWVFVVORNF\wPIRKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=MV2yNFU4OTB4OR?=
A431Ml7vT4lv[XOnIFHzd4F6MXe1JO69VQ>?NU\Dc5NqPSCqMlfjSG1UVw>?NHK5[ZJUfXCycnXzd4V{KHSqZTDzbYdv[Wyrbnegc4YhSWu2IHHu[EBGemt?NVz0bYI6OjB3N{GwOlk>
HepG2NVLD[mVCS3m2b4TvfIlkKEG|c3H5Mn;GNVAh|ryPNVjq[oF3OjRiaB?=MlzqSG1UVw>?NIHvbYJU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI>NVnZemV1OjF{MEW5NlU>
Sk-Hep1NUC4RZBOS3m2b4TvfIlkKEG|c3H5NI[3VVYyOCEQvF2=MknsNlQhcA>?NEPoS|NFVVORMU\T[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK=NWfNbJNUOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+)NH3VdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY[xXlB[OyEQvF2=M3TGclUh\A>?M2nJW2ROW09?NVnoRpRHUUN3ME2wMlE1KM7:TR?=NGLkWVIzOTJ6OUK2Oy=>
K1 cells harbored PIK3CA (E542K+/+)M1PLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXTN{DPxE1?M33LbVUh\A>?M3u1XmROW09?MmHCTWM2OD1yLkWyJO69VQ>?M{jMc|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+)NYj5flBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUCzJO69VQ>?MYi1JIQ>M{HvS2ROW09?NY\zRVYyUUN3ME2wMlE5KM7:TR?=MYCyNVI5QTJ4Nx?=
C643 cells harbored HRAS (G13R+/−)NEnBZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfO[mN6OyEQvF2=MVS1JIQ>NXzkflhDTE2VTx?=M1qyVmlEPTB;MD6yO{DPxE1?Mn3jNlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−)MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHqx[|Y{KM7:TR?=MV[1JIQ>NETB[2JFVVORMX\JR|UxRTRwNTFOwG0>NXXmXJpEOjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangementNFHkfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYmzJO69VQ>?NYfDV5M1PSCmM3TnPWROW09?M2PRfmlEPTB;MD61PUDPxE1?M{XQ[FIyOjh7Mk[3
Hth74NHPnZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[yTFMh|ryPNYrUbIRFPSCmM{C5TmROW09?NEjXSHNKSzVyPUKuNVkh|ryPMkTsNlEzQDl{Nke=
KAT18NVrwXog2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDoN{DPxE1?NF;yVpk2KGR?NH3lVnNFVVORM1r4VmlEPTB;ND62NkDPxE1?M4Dv[FIyOjh7Mk[3
SW1736M4fid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYGxNFAh|ryPNHTBXms2KGR?NFjYPGtFVVORNVfyc|FvUUN3ME20O{42PiEQvF2=M{LD[VIyOjh7Mk[3
WROMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nWdlExODBizszNM3zDRlUh\A>?NIrOTYFFVVORM1T3bWlEPTB-MUCwNEDPxE1?MmLENlEzQDl{Nke=
TAD2MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrtdHUyODByIN88US=>Mn30OUBlMn7VSG1UVw>?MmG5TWM2OD5zMECwJO69VQ>?M3ToNFIyOjh7Mk[3
LN229MmDQRZBweHSxc3nzJGF{e2G7Mn2yNE42KM7:TR?=NWnjfZk3PjBiaB?=NIqyRY5FVVORNXvENFFxSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK=M3jEWVIzODV5OUG0
T98GMXnBdI9xfG:|aYOgRZN{[Xl?MmXjNE42KM7:TR?=NGjaOoM3OCCqMoHFSG1UVw>?MlXiRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ?NIK1VpYzOjB3N{mxOC=>
HC11M2LL[mZ2dmO2aX;uJGF{e2G7NXHkTWpvOTBizszNMofDNlQhcA>?NHXyfnNFVVORMnP3TY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=>M4Hlc|IzPDJ4NkKx
MOLT-4M37UNWN6fG:2b4jpZ{BCe3OjeR?=MUKxNEDPxE1?MoT4OFghcA>?M3TYNmROW09?NF\VfHRKSzVyPUGuO-KBkc7:TR?=NFvRVmEzOjZzNEK0Ny=>
CEM-RM1PQcmN6fG:2b4jpZ{BCe3OjeR?=NFvKc3EyOCEQvF2=NWXjXIZwPDhiaB?=M2T6SWROW09?MlO5TWM2OD1|LkRihKnPxE1?NYXuVJZOOjJ4MUSyOFM>
CEM-SMVLDfZRwfG:6aXOgRZN{[Xl?M3Gy[FExKM7:TR?=MUG0PEBpMVzEUXNQNXXhSIJXUUN3ME21MlHjiIoQvF2=M33tSlIzPjF2MkSz
MOLT-4NGHpdYRHfW6ldHnvckBCe3OjeR?=M4\nOVExKM7:TR?=NIDPR|czPCCqMVzEUXNQNUjKTmpjSmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?=M{\qeVIzPjF2MkSz
MOLT-4NV\kV45sTnWwY4Tpc44hSXO|YYm=MnP1OQKBkc7:TR?=MWK0JIg>M33zZ2ROW09?M3Oyc2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>?MnHnNlI3OTR{NEO=
CEM-RMW\GeY5kfGmxbjDBd5NigQ>?MoK1OQKBkc7:TR?=NEfaO4g1KGh?NIr5eIZFVVORM3LLPWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>?NIT3RpczOjZzNEK0Ny=>
CEM-SNVvmT5lwTnWwY4Tpc44hSXO|YYm=MV:05qCK|ryPNGno[WU1KGh?MoHESG1UVw>?MWDJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI>NXjU[|l2OjJ4MUSyOFM>
HepG2 cellMWjLbY5ie2ViQYPzZZk>NUflWFY5OjBizszNM2T5XVI1KGh?M1HKSmROW09?M2nBR2Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?MYqyN|c6PzNzOR?=
HepG2 cellMkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPYN|Ah|ryPM3jodFI1KGh?MUnEUXNQM1nScGlvcGmkaYTzJINmdGxiZ4Lve5RpM3;jXFI{Pzl5M{G5
HepG2 cellM{W2V2Fxd3C2b4Ppd{BCe3OjeR?=MmTLNlAh|ryPNXfoclRjOjRiaB?=M4DpNWROW09?MYTJcoR2[2W|IHPlcIwh[XCxcITvd4l{MmTuNlM4QTd|MUm=
GEONFm0XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXq1NFAhdk1?NHTESIo4OiCqNUf0TmdITE2VTx?=MmDJTY5pcWKrdIOgZ4VtdCCpcn;3eIg>NHHPdFIzPDV6MUKzNS=>
CNE-1M2HIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYixNEDPxE1?MWC5OkBpNGHY[YtFVVORM12xO2lEPTB;Mj65OkDPxE1?MU[yOVM{Pjl{NR?=
CNE-2NVuwWFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHlNVAh|ryPNYDpOVVYQTZiaB?=NFnuN2tFVVORMVXJR|UxRTRwNUOg{txOMlS3NlU{OzZ7MkW=
HONE-1MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTzNVAh|ryPMYG5OkBpMnTkSG1UVw>?NEm3TI9KSzVyPUOuN|ch|ryPMYSyOVM{Pjl{NR?=
SUNE-1NXi3UVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PJZ|ExKM7:TR?=M2\ke|k3KGh?NFPiTpBFVVORNWq3OGdiUUN3ME2wMlUzKM7:TR?=NYnpdHNqOjV|M{[5NlU>
CNE-2M2\tVmZ2dmO2aX;uJGF{e2G7MVOxNEDPxE1?NGLPeYw1QCCqMYnEUXNQM1zqW2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF?NFnaVIgzPTN|NkmyOS=>
HONE-1MU\GeY5kfGmxbjDBd5NigQ>?MWWxNEDPxE1?NXzIfpJ4PDhiaB?=MV7EUXNQM{LJOmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF?MWeyOVM{Pjl{NR?=
NEC8NVXBOlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnqwTWM2OD1yLkC5OlUyKM7:TR?=MY\TRW5ITVJ?
P12-ICHIKAWANUizTIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\sTWM2OD1yLkGxOlIh|ryPMl6zV2FPT0WU
MDA-MB-175-VIINH\PZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnr1TWM2OD1yLkGzO|M5KM7:TR?=NUnoNpVEW0GQR1XS
AsPC-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLQUJRWUUN3ME2wMlIzOTJ{IN88US=>Mn;VV2FPT0WU
T47DMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vYdmlEPTB;MD6yPFI2KM7:TR?=NXq1XWx5W0GQR1XS
HHMl7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDtfHhSUUN3ME2wMlMxOjh|IN88US=>MV3TRW5ITVJ?
MOLT-16NECxWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q1OWlEPTB;MD6zNFMzKM7:TR?=MkXaV2FPT0WU
ES5NYG5O2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDHXmJKSzVyPUCuN|Q1PTVizszNNFzRcGNUSU6JRWK=
RS4-11NVLTWWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LwWGlEPTB;MD6zOFYyKM7:TR?=NF73eXdUSU6JRWK=
KARPAS-45NYrsNWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwM{ezNlEh|ryPMojtV2FPT0WU
NCI-H720NE\6TWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3pSYV5UUN3ME2wMlM4Pjd7IN88US=>M3fMNHNCVkeHUh?=
H9M2q0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVy2WmY3UUN3ME2wMlM5QDh|IN88US=>NV\ibI04W0GQR1XS
EFM-19NUXoWWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPiUHFKSzVyPUCuOFQxOSEQvF2=MV3TRW5ITVJ?
SBC-1M2TlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nadWlEPTB;MD60OFA{PSEQvF2=MlrhV2FPT0WU
A4-FukM1:3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPzTWM2OD1yLkS2PFY5KM7:TR?=MX7TRW5ITVJ?
NCI-H1563M{naOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\FdoRXUUN3ME2wMlQ5OTh7IN88US=>Mn7pV2FPT0WU
HCC1419MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwNEi4PVIh|ryPMVLTRW5ITVJ?
H-EMC-SSNYfJVpo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHq1bIFKSzVyPUCuOFk6OzlizszNM2XKd3NCVkeHUh?=
BHT-101NYnvR2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfRRplKSzVyPUCuOVI6PjFizszNM1PCSnNCVkeHUh?=
IGROV-1NWrKb|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe4NodKSzVyPUCuOVUzPDlizszNM1XCVnNCVkeHUh?=
HGC-27M{LtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzQbpNPUUN3ME2wMlU3Pzh|IN88US=>NV;aXFM2W0GQR1XS
MDA-MB-361NH\YVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDvTWM2OD1yLkW3O|YyKM7:TR?=NH7JN3pUSU6JRWK=
KE-37M{jwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL1TWM2OD1yLkW4NlYh|ryPMkfFV2FPT0WU
HCC70MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjTPVVoUUN3ME2wMlU6QDJ5IN88US=>M1jhRnNCVkeHUh?=
LNCaP-Clone-FGCNE\rU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu1OFBKSzVyPUCuOlExPDhizszNM33ZSnNCVkeHUh?=
HAL-01NITtSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwNkKxN{DPxE1?NE\oV4FUSU6JRWK=
HTNFPWRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3q3cWlEPTB;MD62N|I{QSEQvF2=MlrUV2FPT0WU
MDA-MB-415MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfQTWM2OD1yLk[zOlI3KM7:TR?=Ml[3V2FPT0WU
NOS-1NITuTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmj0TWM2OD1yLk[zO|I{KM7:TR?=M3\JNXNCVkeHUh?=
DU-145NILOS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwNkS3OFUh|ryPMke2V2FPT0WU
OCUB-MMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nHU2lEPTB;MD63NFk3PiEQvF2=NGL3VWRUSU6JRWK=
VA-ES-BJNFW5T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrrNXBKSzVyPUCuO|MxOjVizszNMnPXV2FPT0WU
J-RT3-T3-5NID1ZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETNfGxKSzVyPUCuO|Q1ODNizszNNX33W4ZDW0GQR1XS
MOLT-4M3;DV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTBwOEC1PFIh|ryPNUHBd4VYW0GQR1XS
NB7NFztd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\UeGlEPTB;MD64NlQyOSEQvF2=MVvTRW5ITVJ?
L-363NWXxZVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4W5UWlEPTB;MD64N|Q1OiEQvF2=M1HJRXNCVkeHUh?=
NKM-1NHnwc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LoNmlEPTB;MD64OlI2OyEQvF2=NVfS[5dYW0GQR1XS
HOP-92M{jIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnQWnpKSzVyPUCuPFczOjNizszNNInRN45USU6JRWK=
OAW-42NYPVTZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXRdmpKSzVyPUCuPFg4OiEQvF2=NXnjSIxKW0GQR1XS
HuO9M33MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWCxeG9VUUN3ME2wMlkzPzVzIN88US=>NIjufGtUSU6JRWK=
MFE-280MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfxXlRDUUN3ME2wMlk3PDZ3IN88US=>NEjwZ4pUSU6JRWK=
EM-2M37OfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvScXV2UUN3ME2wMlk4QTN7IN88US=>MYXTRW5ITVJ?
NCI-H520Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XSbGlEPTB;MD65PFU6OiEQvF2=MV;TRW5ITVJ?
LB2241-RCCMmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HYTWlEPTB;MD65PVc{PCEQvF2=M{HZWHNCVkeHUh?=
SK-NEP-1NXjmcIE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nBemlEPTB;MT6xOFQ5PSEQvF2=NHjTfZlUSU6JRWK=
LXF-289M1HsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ThR2lEPTB;MT6xO|E2PiEQvF2=Ml3kV2FPT0WU
EPLC-272HNYjK[GZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFwMUeyOVYh|ryPM{\mV3NCVkeHUh?=
COLO-684NUnkXW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjNXGxWUUN3ME2xMlI{PzJ3IN88US=>NV61dYRkW0GQR1XS
ES1NV7IPWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkS5TWM2OD1zLkK0NFY2KM7:TR?=NFfIOpdUSU6JRWK=
DOHH-2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\ITWM2OD1zLkK4NlA{KM7:TR?=M4LJZXNCVkeHUh?=
CTB-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTFwMki5PUDPxE1?Mmq3V2FPT0WU
G-401NEiwT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFP0eIdKSzVyPUGuNlk4QTVizszNM2DjR3NCVkeHUh?=
LoVoM4XpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXx[W54UUN3ME2xMlMzPTN2IN88US=>M13afHNCVkeHUh?=
Ramos-2G6-4C10NFK2OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEX5dG5KSzVyPUGuN|M4ODFizszNM3TIT3NCVkeHUh?=
MFM-223M4e2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFwM{S0OlEh|ryPMmHiV2FPT0WU
PA-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXm2N2N1UUN3ME2xMlM2OjZ3IN88US=>NXG2ZoVCW0GQR1XS
697MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m1WGlEPTB;MT6zO|YyPiEQvF2=M1rYOHNCVkeHUh?=
QIMR-WILMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH[3dYNKSzVyPUGuOFkyOTZizszNNHradVhUSU6JRWK=
HOSMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrUcWhKSzVyPUGuOFk2PThizszNMYTTRW5ITVJ?
DMS-273NWS5WphbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX1V2FKSzVyPUGuOVE6PTlizszNNX3uTWl5W0GQR1XS
ME-180MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFwNU[4PVEh|ryPMoSyV2FPT0WU
HCC2218M3nXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrGTWM2OD1zLk[4NlI2KM7:TR?=NUe0RpBqW0GQR1XS
CAL-54M1S5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTnO3REUUN3ME2xMlcyOjR{IN88US=>NV3XXZNOW0GQR1XS
OMC-1MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHyXoNKSzVyPUGuO|Q3PzdizszNMYnTRW5ITVJ?
COR-L105MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELJOVBKSzVyPUGuO|k4OzdizszNMWXTRW5ITVJ?
BV-173MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTFwOEGwO|Qh|ryPNVzPbY14W0GQR1XS
RKOM{PJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jDRmlEPTB;MT64O|ExOSEQvF2=NX;xdWJDW0GQR1XS
SNU-387NYK3OZJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHZTWM2OD1zLki4OFA3KM7:TR?=NFnMeotUSU6JRWK=
SW1088MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF73N3hKSzVyPUGuPVQ3ODZizszNMUTTRW5ITVJ?
Hs-578-TMnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfiTWM2OD1{LkGxOFM{KM7:TR?=MoXTV2FPT0WU
OC-314Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJwMUWwPFYh|ryPMXXTRW5ITVJ?
RMG-IMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV33V5NxUUN3ME2yMlE3Ozl6IN88US=>Mlf4V2FPT0WU
NCI-H1395MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjKd493UUN3ME2yMlE5ODlzIN88US=>NIW2fJhUSU6JRWK=
GAMGNWLLdGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ntZWlEPTB;Mj6yN|g1PSEQvF2=MX;TRW5ITVJ?
LB1047-RCCNXewbYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13wVGlEPTB;Mj6yOFMyPyEQvF2=M4jKTXNCVkeHUh?=
MN-60M{DidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml33TWM2OD1{LkK5PVI{KM7:TR?=NFe3TY1USU6JRWK=
OAW-28MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTJwMkm5OVEh|ryPMVnTRW5ITVJ?
NCI-H2228NYXBTIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojyTWM2OD1{LkOxOVUzKM7:TR?=NU\hdW5DW0GQR1XS
ABC-1NFTmVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfOTWM2OD1{LkOzNlU{KM7:TR?=MkT1V2FPT0WU
LS-513MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nHeGlEPTB;Mj6zN|Q5PCEQvF2=M4PlbXNCVkeHUh?=
KS-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHhb2dKSzVyPUKuN|gyQTFizszNNILy[JZUSU6JRWK=
NB69MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJwM{i5PFMh|ryPNUfueFY{W0GQR1XS
VM-CUB-1NV\ZUm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XWRWlEPTB;Mj6zPVA5OyEQvF2=M4DObHNCVkeHUh?=
D-423MGM2L1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJwNEGwOFQh|ryPNIXuZY9USU6JRWK=
EW-18M3;uS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfxTWM2OD1{LkSxPVM6KM7:TR?=NY\TV3duW0GQR1XS
YH-13NWP4[XNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4X2[GlEPTB;Mj60OlE2OyEQvF2=Ml60V2FPT0WU
T-24NGf2NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH63T|NKSzVyPUKuOFc5QDFizszNMYXTRW5ITVJ?
ES8NVfYVYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzrbIM6UUN3ME2yMlQ6Ojh5IN88US=>MnLlV2FPT0WU
ES3NYnVZmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\tTWM2OD1{LkS5O|U6KM7:TR?=MYXTRW5ITVJ?
RXF393M2\tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvmeGZKSzVyPUKuOlA1QDdizszNM4HMW3NCVkeHUh?=
RPMI-8226NXLLOnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm3cJdKSzVyPUKuOlI6PTNizszNMlP3V2FPT0WU
AGSMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljxTWM2OD1{LkeyNVM4KM7:TR?=M{XUXHNCVkeHUh?=
HCC1395NWLsZYZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrTfI9PUUN3ME2yMlc2OTh5IN88US=>M4C3dnNCVkeHUh?=
MV-4-11NWjtR2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIC1PGNKSzVyPUKuO|UzPjZizszNMl;sV2FPT0WU
A204NHHEUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\NNI9nUUN3ME2yMlg{QDd{IN88US=>M{Tab3NCVkeHUh?=
MCF7M3nabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlj5TWM2OD1{Lki2NVE4KM7:TR?=MXvTRW5ITVJ?
SNU-423MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfS[2IyUUN3ME2yMlg6OjR{IN88US=>MkHkV2FPT0WU
NCI-H1048NU\FS3BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV6zbppNUUN3ME2yMlk3QDZ3IN88US=>NHT2eJpUSU6JRWK=
GR-STMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTtU|RqUUN3ME2zMlA1PjFzIN88US=>MX\TRW5ITVJ?
EoL-1-Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3iUopEUUN3ME2zMlA4ODV6IN88US=>Ml3kV2FPT0WU
HuH-7NYr6TopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTNwMEm0OlQh|ryPM4K4UHNCVkeHUh?=
OS-RC-2MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjWc5ZiUUN3ME2zMlEyOTlizszNNYDNZY1jW0GQR1XS
EW-3M{LRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDpTmRKUUN3ME2zMlE6PTJ7IN88US=>NVjscXBiW0GQR1XS
NCI-H747NV:xd5JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zrbGlEPTB;Mz6yNFY6PCEQvF2=MkC0V2FPT0WU
EW-16NVr1WnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL4TWM2OD1|LkKxPFc6KM7:TR?=M4XoS3NCVkeHUh?=
DOKMnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPOTWM2OD1|LkKyPFU6KM7:TR?=NX\Fd2VrW0GQR1XS
HCC2157NUPyTJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\0b5JIUUN3ME2zMlM5OTd7IN88US=>NHnLUWxUSU6JRWK=
OVCAR-3MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXoTWM2OD1|LkSwO|g3KM7:TR?=NHzVN2ZUSU6JRWK=
NCI-H1623M4nIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTNwNEGyNlQh|ryPMVTTRW5ITVJ?
H4M2DobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7XTWM2OD1|LkS1OlI3KM7:TR?=M3\tTnNCVkeHUh?=
SW1710MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTNwNE[2O|gh|ryPNFjJRpdUSU6JRWK=
RT-112MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYf1T4NNUUN3ME2zMlUzOzh6IN88US=>NIHQNXFUSU6JRWK=
DMS-114M33Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGX3OFBKSzVyPUOuOlIzPzhizszNNEW3T2ZUSU6JRWK=
AN3-CAM37TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrWTWM2OD1|Lk[yOFU3KM7:TR?=M4nWZXNCVkeHUh?=
KNS-62NWPNVlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DrbWlEPTB;Mz62N|M{QCEQvF2=M2nCRXNCVkeHUh?=
SJRH30MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rDUWlEPTB;Mz62PVEzOiEQvF2=MYHTRW5ITVJ?
G-402M1;FO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPY[IxKSzVyPUOuO|A4OTFizszNNU\lO2RLW0GQR1XS
MHH-PREB-1M2jwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fBcmlEPTB;Mz63NlA{QCEQvF2=NV\sVHVXW0GQR1XS
P30-OHKNW\JS5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnW2TWM2OD1|LkiwPVc3KM7:TR?=MoP2V2FPT0WU
RVH-421NFrTS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTNwOEG3PFgh|ryPMYXTRW5ITVJ?
LU-134-ANI[3b3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTNwOEi0Nlgh|ryPNHKzTmRUSU6JRWK=
ECC10NVfxUWdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HBU2lEPTB;Mz65N|YzOiEQvF2=NWftNVFOW0GQR1XS
TGWNGHXZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTRwMEKzNFUh|ryPNFXQUYtUSU6JRWK=
MLMANWr0RYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPCXpFKSzVyPUSuNFI6PjZizszNNILEcmpUSU6JRWK=
SCC-25MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLSTWM2OD12LkC2OVY3KM7:TR?=NUHjd2hsW0GQR1XS
TYK-nuMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTRwMEm1N|Qh|ryPMn62V2FPT0WU
LAMA-84Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTRwMUSxPVEh|ryPNH3GVJZUSU6JRWK=
Calu-3MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTRwMkS0NVYh|ryPMnLlV2FPT0WU
NCI-H460MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInSbZBKSzVyPUSuNlY1PDNizszNMWDTRW5ITVJ?
EGI-1M1i5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfoW4RKSzVyPUSuN|c4PzhizszNMnHoV2FPT0WU
NCI-H292MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTRwM{ixOFYh|ryPM1\CZXNCVkeHUh?=
HCE-TNIDj[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnGXldKSzVyPUSuOFE2PzlizszNMV3TRW5ITVJ?
EW-11M1W4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;KUGlEPTB;ND60NVg{QCEQvF2=M3HodnNCVkeHUh?=
ATN-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTRwNESzNFQh|ryPM{PPVHNCVkeHUh?=
NB5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTRwNUO2PVch|ryPM2OwR3NCVkeHUh?=
KLEM1XxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTRwN{CxPVgh|ryPMl3zV2FPT0WU
CAL-39MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHToW|JKSzVyPUSuO|IyPDZizszNNXvCO49mW0GQR1XS
TI-73MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTRwOEC2NFkh|ryPM2LCXHNCVkeHUh?=
HO-1-N-1Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTRwOUSyJO69VQ>?NVi1ZY5zW0GQR1XS
786-0NFzLR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXDTHdmUUN3ME20Mlk1Pjd|IN88US=>M2T1PXNCVkeHUh?=
SK-N-DZNVfNOG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{W3WWlEPTB;ND65OlE1OiEQvF2=Ml;VV2FPT0WU
NCI-H446NHnKNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTVwMkCwNFkh|ryPNXXjSFNHW0GQR1XS
ETK-1NXjGV4hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnYXmx2UUN3ME21MlIyOTZ3IN88US=>NVLXR|RbW0GQR1XS
BT-20NHX6[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTVwMkGzOVMh|ryPMl3JV2FPT0WU
MEL-HOMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXT[5pQUUN3ME21MlM4OzN4IN88US=>NGnSeYlUSU6JRWK=
CAL-27M1Luemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTVwNE[zN|kh|ryPMnOwV2FPT0WU
SW872NXnaRXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jLNGlEPTB;NT61PVQzQCEQvF2=NXu1VY1uW0GQR1XS
RPMI-2650MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTqTWM2OD13Lk[2NVk6KM7:TR?=MoizV2FPT0WU
PFSK-1NHv2NGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\JTWM2OD13LkeyO|MzKM7:TR?=MoP1V2FPT0WU
SF295NHHnW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTsT4xDUUN3ME21MlgxPjN|IN88US=>NFvBOGdUSU6JRWK=
BeckerM{XKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M133cWlEPTB;NT64OlQ4OiEQvF2=NUnVVXprW0GQR1XS
Saos-2M3;hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TxcGlEPTB;NT64OlU{KM7:TR?=NIDsUYRUSU6JRWK=
SK-OV-3M3zSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXObWpKSzVyPUWuPVk5OTZizszNM3G2O3NCVkeHUh?=
VMRC-RCZNEfrfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTZwMEi3O|Mh|ryPNULKeGNUW0GQR1XS
EW-22NUfV[IVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XmZ2lEPTB;Nj6xPVY1QSEQvF2=MV;TRW5ITVJ?
BT-474NVnsUJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7rSmp3UUN3ME22MlI{OyEQvF2=M1rVSnNCVkeHUh?=
BFTC-909NH\rPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4La[GlEPTB;Nj6zNFM1PSEQvF2=NWPRO5lDW0GQR1XS
NB12NVe3WmJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3q4XWlEPTB;Nj6zPVA4OSEQvF2=M{jQSXNCVkeHUh?=
D-263MGNYjsUFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITNTlBKSzVyPU[uOFUyPjlizszNMkXNV2FPT0WU
SNB75NWPlNHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTZwNkCxOFMh|ryPM3fWVnNCVkeHUh?=
A704MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTZwNkOwOkDPxE1?MYjTRW5ITVJ?
NCI-H1693MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUT4[Y1nUUN3ME22MlY{PjB2IN88US=>NXvVTIZsW0GQR1XS
LN-405MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zNOGlEPTB;Nj63PVY4OiEQvF2=NGjCUHpUSU6JRWK=
CHL-1NGTVVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPJfpd3UUN3ME22MlgxODd7IN88US=>Mmn1V2FPT0WU
A498MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTZwOEG5OlEh|ryPNVe2OmhbW0GQR1XS
TE-12MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPEUZJKSzVyPU[uPFM5OTdizszNNV21[ItmW0GQR1XS
TE-6MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTZwOUOwN|gh|ryPMn\4V2FPT0WU
AU565M{D0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3O[2pzUUN3ME22Mlk3QTV5IN88US=>M1vKbXNCVkeHUh?=
RDM3\HOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnruTWM2OD14Lkm4Nlg1KM7:TR?=NHzjPJpUSU6JRWK=
SW1463M13KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnuTWM2OD15LkGxNVY5KM7:TR?=NXXWUpB1W0GQR1XS
LU-99AMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXwRmw5UUN3ME23MlE1OzJ{IN88US=>NGL6cIlUSU6JRWK=
NCI-H28NFXHVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTdwMkmyOEDPxE1?MmS5V2FPT0WU
MC-IXCMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXjTWM2OD15LkS4OVc3KM7:TR?=MlTxV2FPT0WU
GP5dNYjYWlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XzPWlEPTB;Nz60PFc3PCEQvF2=MWLTRW5ITVJ?
GB-1NHP5Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4C4OGlEPTB;Nz61OFgxPCEQvF2=MoD6V2FPT0WU
CAL-33NInYV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDw[GNKSzVyPUeuOlYzOzNizszNMln2V2FPT0WU
MSTO-211HNF7zSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTdwNkezN|Yh|ryPMljCV2FPT0WU
TE-5MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPJT5RIUUN3ME23Mlc6OzN2IN88US=>NXTZdo5HW0GQR1XS
D-566MGM2C5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRThwMES0Nlkh|ryPNGHQNGRUSU6JRWK=
JVM-3Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fLfmlEPTB;OD6xOVI3QCEQvF2=MX;TRW5ITVJ?
T98GMn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI[xc29KSzVyPUiuNVgxPjdizszNNITkWXNUSU6JRWK=
HCC1954NWrHWnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfBb2NKSzVyPUiuOFUyODRizszNNIDqcXRUSU6JRWK=
SF126NXPtdJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRThwNEW5N|Yh|ryPMlLqV2FPT0WU
LB996-RCCNWnrR3A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm2TWM2OD16LkWzNlU4KM7:TR?=NFO5S21USU6JRWK=
SKG-IIIaNUD5R29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRThwNkOwOlkh|ryPNWqwXGVMW0GQR1XS
NCI-SNU-1NYr6SFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRThwNkS2OFMh|ryPMnL0V2FPT0WU
LB771-HNCMoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjvdnkyUUN3ME24MlY1Pjl4IN88US=>M3rtfHNCVkeHUh?=
SCC-4M2Gz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRThwNkiyNVkh|ryPNF[3ZlZUSU6JRWK=
CAMA-1NULrPGhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRThwN{exOFYh|ryPMV\TRW5ITVJ?
D-502MGNVr2fGpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXWw[29[UUN3ME24Mlc5PjJ7IN88US=>NYTPSZp{W0GQR1XS
ESS-1NHexSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDlZYdJUUN3ME24Mlg5PzB2IN88US=>Ml;mV2FPT0WU
HEC-1NGK1dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEm0b5dKSzVyPUiuPFk5PjZizszNNXPvSIw6W0GQR1XS
NB10M2n1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPWOpFKSzVyPUmuNFIzOjRizszNMmG1V2FPT0WU
8505CMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjZVo1HUUN3ME25MlA1OjN{IN88US=>NGnXZndUSU6JRWK=
EFO-27NVmxWnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTlwMU[0NVIh|ryPNXXSdWJyW0GQR1XS
HNMlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y2dGlEPTB;OT6xOlYzQCEQvF2=NWXEWIUxW0GQR1XS
DSH1NV7QR5VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDmcHhKSzVyPUmuNlA5PyEQvF2=NGHFbY1USU6JRWK=
NBsusSRMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTlwMke0NFIh|ryPNF20dGdUSU6JRWK=
LS-123MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTlwM{G3OlEh|ryPM2T0W3NCVkeHUh?=
SHP-77NX\XWpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{[xN2lEPTB;OT6zPVk{PSEQvF2=M1H0VnNCVkeHUh?=
ACNMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\KfYloUUN3ME25MlU{Ojd5IN88US=>MYXTRW5ITVJ?
U251NV3Zd4NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\3TWM2OD17Lk[1OVQ1KM7:TR?=MWnTRW5ITVJ?
A431NV7KeHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrjblhKSzVyPUmuPFAzOzhizszNMUXTRW5ITVJ?
5637NVHlWVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXOVIwxUUN3ME25Mlg1QTh2IN88US=>NFv1UVBUSU6JRWK=
MDA-MB-157MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnyRWNqUUN3ME25MlkzQDd6IN88US=>M{jjZXNCVkeHUh?=
A101DM4Txe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\mTWM2OD17Lkm5PVc1KM7:TR?=M3nWWXNCVkeHUh?=
YKG-1MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnhPVNKSzVyPUGwMlIxODZizszNNHrYW|FUSU6JRWK=
LAN-6MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzCOohpUUN3ME2xNE4zOTZ2IN88US=>NUL6NmJrW0GQR1XS
OVCAR-5M{DV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjoTWM2OD1zMD6yOFM{KM7:TR?=M3izPXNCVkeHUh?=
A549NYnmRVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjhWXdKSzVyPUGwMlM6PzNizszNNV\5N5c1W0GQR1XS
no-11M1;YPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\yTWM2OD1zMD60N|U{KM7:TR?=M1HpWHNCVkeHUh?=
SF539NH;YWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHPZVg5UUN3ME2xNE46ODRzIN88US=>NX;D[pRrW0GQR1XS
A388NGC5SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFzLkO4PVch|ryPM{jGdnNCVkeHUh?=
DELNVH5THB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LWRWlEPTB;MUGuOFI1KM7:TR?=M2LadnNCVkeHUh?=
SW954NXv6UnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TJZ2lEPTB;MUGuOFY3QCEQvF2=NFnsXnJUSU6JRWK=
TK10NX;pbWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfTeHJKSzVyPUGxMlUzPzFizszNMmTlV2FPT0WU
SW756MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjRTWM2OD1zMT61Nlk1KM7:TR?=NWXKPZFvW0GQR1XS
PC-3MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXxZnJoUUN3ME2xNU42PzZ2IN88US=>M2PTUnNCVkeHUh?=
ONS-76MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLNfXlYUUN3ME2xNU43OzZizszNMWnTRW5ITVJ?
A427M1;oT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvGR2hXUUN3ME2xNU44ODl|IN88US=>NHjkSIJUSU6JRWK=
MEG-01NW[1VYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj3Xm9nUUN3ME2xNU44PTB7IN88US=>M135XXNCVkeHUh?=
BB30-HNCNXnuTXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPYdpFKSzVyPUGxMlc6QDJizszNNFnZXGZUSU6JRWK=
NCI-H1299NXj0[FZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;GPIVKSzVyPUGxMlgxQTNizszNM3SzVXNCVkeHUh?=
GCTM4\1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\lZlFKSzVyPUGxMlgzOjhizszNMV3TRW5ITVJ?
D-247MGNXHqSHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7xTWM2OD1zMT65OlY{KM7:TR?=NW\iV4FMW0GQR1XS
CFPAC-1NEjLWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFO3OI1KSzVyPUGxMlk4QDJizszNM4W4WXNCVkeHUh?=
EKVXNYflenFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7vTWM2OD1zMj6wN|E{KM7:TR?=NXX2flJSW0GQR1XS
CAL-51M2nwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrwTWM2OD1zMj6wO|E3KM7:TR?=MnPWV2FPT0WU
BB49-HNCNVjvc3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDFTWM2OD1zMj6xNVc4KM7:TR?=MlPUV2FPT0WU
RPMI-7951M4jEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXrTWM2OD1zMj6xPFU1KM7:TR?=NHfNb2xUSU6JRWK=
RH-1NF;oboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF{LkKxPFQh|ryPNHf0Wm5USU6JRWK=
BCPAPM{mzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rBfWlEPTB;MUKuOFc1QSEQvF2=NEHmR5lUSU6JRWK=
GCIYM1\PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknsTWM2OD1zMj61NlA6KM7:TR?=M{K5SXNCVkeHUh?=
KNS-81-FDMlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7SeZZKSzVyPUGyMlU5PjlizszNM4LBcnNCVkeHUh?=
KYSE-140M{H5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml74TWM2OD1zMj64OVk2KM7:TR?=NXO5fmh5W0GQR1XS
Ca-SkiNX64V41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF{LkmwOFEh|ryPNX;2NXk{W0GQR1XS
TGBC1TKBM1[3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\rRmlEPTB;MUKuPVEyPSEQvF2=NWfW[oxiW0GQR1XS
HCC1187MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTF|LkG5NVIh|ryPM4\3d3NCVkeHUh?=
SJSA-1NFrYWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7hTWM2OD1zMz6yN|I4KM7:TR?=NYrBZ|hwW0GQR1XS
CTV-1NV\GNYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTF|LkO0OUDPxE1?NH;4PFFUSU6JRWK=
WM-115NE\EUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTF|Lk[0PFMh|ryPNGPJT|JUSU6JRWK=
CHP-212NIn0T5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jCW2lEPTB;MUOuPVc{QSEQvF2=MlXaV2FPT0WU
SCC-15NHjifnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXMTWM2OD1zMz65O|c2KM7:TR?=NGPBbYlUSU6JRWK=
BPH-1NWPZTFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fGW2lEPTB;MUSuNVY3PCEQvF2=MoW4V2FPT0WU
SW780NFnUbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2D2TmlEPTB;MUSuOVAzPSEQvF2=MUDTRW5ITVJ?
NCI-H2291NXTFPVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\iV2lEPTB;MUSuOVg4QCEQvF2=MYTTRW5ITVJ?
JEG-3NVG3Umd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojETWM2OD1zND62N|I3KM7:TR?=MlPRV2FPT0WU
CAL-120Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTF2LkewNlch|ryPNHLtfWpUSU6JRWK=
NCI-H23MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\TTWM2OD1zND63PVk4KM7:TR?=MkfZV2FPT0WU
MS-1M2L4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\NcIVKSzVyPUG0Mlk3OTFizszNNVXOc2tDW0GQR1XS
PC-14M3XuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LNTWlEPTB;MUSuPVY2PCEQvF2=NFT1WIpUSU6JRWK=
D-283MEDMljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;yTWM2OD1zNT6wNVEyKM7:TR?=MnK0V2FPT0WU
OE19NFKxcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVKzeGtpUUN3ME2xOU4yPTRzIN88US=>MmDYV2FPT0WU
CAS-1NIfwPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fCPGlEPTB;MUWuOFE5PCEQvF2=MWnTRW5ITVJ?
NCI-H727M1K3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDKTWM2OD1zNT60NlIyKM7:TR?=MmfOV2FPT0WU
SiHaNIDCXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfvWmtKSzVyPUG1Mlc2QTRizszNM2fp[3NCVkeHUh?=
BFTC-905M{frWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTF3Lke2PVQh|ryPMmrEV2FPT0WU
MDA-MB-453MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXv3NmZOUUN3ME2xOk4yPjR{IN88US=>MXTTRW5ITVJ?
HuP-T3M1HYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XCd2lEPTB;MU[uOlM4OyEQvF2=NUn3b2tXW0GQR1XS
SK-LU-1NWfSboQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\qdlRKSzVyPUG2MlY6PTZizszNMkHjV2FPT0WU
Detroit562NHzNVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2r4cGlEPTB;MU[uO|MyQCEQvF2=Mk\rV2FPT0WU
HCC1569MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVmwU2ZvUUN3ME2xOk45OzN5IN88US=>NIPWUVVUSU6JRWK=
SK-MES-1Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrBc3FKSzVyPUG2Mlg1OTlizszNM2DaTnNCVkeHUh?=
BB65-RCCMontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XHWWlEPTB;MUeuNFQ4QSEQvF2=NXizVo1mW0GQR1XS
LOXIMVINWr6SZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTF5LkC3NFch|ryPMXPTRW5ITVJ?
SW1783NHjIUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTF5LkGyPEDPxE1?NUGwZm5RW0GQR1XS
NH-12MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzITWM2OD1zNz6zN|A{KM7:TR?=NFvlOmNUSU6JRWK=
UACC-257M1\WPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHSTWM2OD1zNz61OVEzKM7:TR?=MoruV2FPT0WU
KOSC-2M3PHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfJeFR[UUN3ME2xO{43PzV5IN88US=>NI\kbpFUSU6JRWK=
KG-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfJW49KSzVyPUG3MlY6OzdizszNM2[4SnNCVkeHUh?=
M059JM3LlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzQbIxFUUN3ME2xO{44ODNizszNNGLqXmRUSU6JRWK=
MHH-NB-11NYfrPFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{O5R2lEPTB;MUeuPVY4OyEQvF2=M1LkXXNCVkeHUh?=
EW-1NV7KbWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzU[3BKSzVyPUG4MlE{QDJizszNNYXROmxzW0GQR1XS
CAL-85-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnme2lYUUN3ME2xPE4zOzV5IN88US=>M4XWc3NCVkeHUh?=
639-VMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnQXZRrUUN3ME2xPE4{OzV2IN88US=>MXLTRW5ITVJ?
C32M4LZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTF6LkS3Nlch|ryPNWXOTVE6W0GQR1XS
KM-H2MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTF6LkWyN|Ih|ryPNY\yO|BjW0GQR1XS
A253NFzTV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrFTWM2OD1zOD63Nlg3KM7:TR?=NYDRb4VrW0GQR1XS
NCI-N87NFm2d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXEd|h1UUN3ME2xPE46ODB6IN88US=>MYDTRW5ITVJ?
8-MG-BANW\vZpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTF7LkC2OFYh|ryPNHXPN3NUSU6JRWK=
GI-ME-NMoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;rN5ZKSzVyPUG5MlE2PDZizszNMkjCV2FPT0WU
8305CMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfING5KSzVyPUG5MlIzQDZizszNMl3NV2FPT0WU
TE-8MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO4TWM2OD1zOT6zNFI1KM7:TR?=MV\TRW5ITVJ?
KYSE-270M4D4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTOTWM2OD1{MD6wNlE4KM7:TR?=MWfTRW5ITVJ?
HL-60MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX74ZVRTUUN3ME2yNE4xQTRzIN88US=>NFvENYJUSU6JRWK=
Mo-TMl\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnTc2dKSzVyPUKwMlE3PjVizszNNUi4W4dmW0GQR1XS
NCI-H1355M3jx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrNTWM2OD1{MD6zN|c1KM7:TR?=NUT3enNUW0GQR1XS
HT-1080M2P3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPJTWM2OD1{MD61OFk4KM7:TR?=MlXiV2FPT0WU
MIA-PaCa-2NVnVNpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\HNGlEPTB;MkCuOlg5OyEQvF2=NHvNdFVUSU6JRWK=
NCI-H441NUDJR|hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPCXGt[UUN3ME2yNE44Ozd7IN88US=>NGn6ZVFUSU6JRWK=
LCLC-97TM1NV76NJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTtTWM2OD1{MD64NVM1KM7:TR?=M2XudnNCVkeHUh?=
HT-3M4P2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Lr[2lEPTB;MkGuOVY{OSEQvF2=M3vn[nNCVkeHUh?=
22RV1M3XCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPNTWM2OD1{MT61Olg2KM7:TR?=NFi5[oVUSU6JRWK=
LK-2NFi0U29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmO4TWM2OD1{MT61PVU{KM7:TR?=M2rmUXNCVkeHUh?=
CW-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTJzLk[wOlkh|ryPM4PGenNCVkeHUh?=
KYSE-510MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFH6emlKSzVyPUKxMlYxQTVizszNNGLqT2tUSU6JRWK=
CGTH-W-1NXfsRWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HHOGlEPTB;MkGuO|E3PiEQvF2=Mli2V2FPT0WU
NCI-H661M1jpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXJTWM2OD1{Mj6wN|Qh|ryPNG[0NlhUSU6JRWK=
KU-19-19NH\X[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrMO3pKSzVyPUKyMlE3QTdizszNMX7TRW5ITVJ?
NCI-H2122MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TOemlEPTB;MkKuNlQ{OiEQvF2=Ml\UV2FPT0WU
NCI-H526M3HES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTJ{LkO4PVUh|ryPM2juO3NCVkeHUh?=
NCI-H1650NUPuOGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm2VopKSzVyPUKyMlc3PCEQvF2=MXzTRW5ITVJ?
AM-38NW\hXY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTJ{Lki2PFkh|ryPMnfjV2FPT0WU
NCI-H2405M4Tscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmC2TWM2OD1{Mz6yOVM{KM7:TR?=NVS2dZFMW0GQR1XS
M14NXnGZ|U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3frS2lEPTB;MkOuOFA5QCEQvF2=NV:3Z4ZPW0GQR1XS
ES4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXpVGNHUUN3ME2yN{41OjN{IN88US=>M3jvUXNCVkeHUh?=
DJM-1NV7PeIcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\0UWJKSzVyPUKzMlUzOzRizszNNWSxZoxXW0GQR1XS
S-117M4XFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL6TWM2OD1{Mz63OlUyKM7:TR?=M{HUenNCVkeHUh?=
MZ2-MELNGjrTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTJ|Lke3OVkh|ryPNWDLfmZ5W0GQR1XS
SK-MEL-2MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTJ|LkixN|Mh|ryPM2HJdHNCVkeHUh?=
HCC1806NIf2[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{e3cWlEPTB;MkOuPFcxQSEQvF2=MVTTRW5ITVJ?
NMC-G1NEXZNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTaTWM2OD1{ND6yNlI3KM7:TR?=NH\lSG1USU6JRWK=
DK-MGNFjiXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXNNo8yUUN3ME2yOE4zQTRizszNMlXjV2FPT0WU
SK-N-FINUjtVlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTJ2LkOzNFIh|ryPMUTTRW5ITVJ?
KINGS-1M1HmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELnXJFKSzVyPUK0MlQ5PzRizszNNGnaOnJUSU6JRWK=
HCC2998Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJ2LkS4PFUh|ryPNGLmd2hUSU6JRWK=
ALL-PONFvYW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEj6OGNKSzVyPUK0MlYyQSEQvF2=M1r5W3NCVkeHUh?=
MPP-89NXz0Z|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjsdphKSzVyPUK1MlA1PThizszNM3\2enNCVkeHUh?=
NCI-H2342NIKwdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:5Z4NXUUN3ME2yOU4yQTV|IN88US=>MVvTRW5ITVJ?
TE-1Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkGyTWM2OD1{NT6zOVY{KM7:TR?=M4frVHNCVkeHUh?=
RH-18NWjBdG91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnrRYFKSzVyPUK1MlU6OThizszNM321O3NCVkeHUh?=
HT-1376NXPOdo5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4n3cmlEPTB;MkWuOlQ3PSEQvF2=MnfLV2FPT0WU
U-2-OSNUW2b5ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXuTWM2OD1{NT62PFg5KM7:TR?=MV\TRW5ITVJ?
BT-549MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\OOY8zUUN3ME2yOU46ODFzIN88US=>MYXTRW5ITVJ?
NCI-H1755NGDuUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f6dGlEPTB;MkWuPVk1PSEQvF2=NFvnXXdUSU6JRWK=
EW-13MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJ4LkCyO|Qh|ryPMV7TRW5ITVJ?
NB13NVjvdG1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjzOGVEUUN3ME2yOk4xQTR7IN88US=>MkW0V2FPT0WU
NUGC-3NVruNno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVr0[ZVMUUN3ME2yOk4zOTB|IN88US=>NFXoS3ZUSU6JRWK=
GMS-10NIfCd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLhTWM2OD1{Nj6yN|U{KM7:TR?=MnLUV2FPT0WU
CHP-134NXq0bnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJ4LkO4Olch|ryPMoS1V2FPT0WU
SW962MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjUU5VMUUN3ME2yOk42ODJzIN88US=>NIK1SGpUSU6JRWK=
SNU-449NGrZXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFO2XIpKSzVyPUK3MlA5ODNizszNNXLWOmFiW0GQR1XS
HuP-T4M{n4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jWfmlEPTB;MkeuNFg4QSEQvF2=MVnTRW5ITVJ?
SW948M{DYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIP4dIlKSzVyPUK3MlE{PDRizszNNFr0TXdUSU6JRWK=
NCI-H226Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjtdXAyUUN3ME2yO{41PTd6IN88US=>MXnTRW5ITVJ?
SK-PN-DWMnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nWb2lEPTB;MkeuOlAyOiEQvF2=MmnSV2FPT0WU
GI-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnT3TWM2OD1{Nz63NlEh|ryPNF33Xm5USU6JRWK=
CAL-12TMlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTldnp3UUN3ME2yPE4yOTF{IN88US=>MlrMV2FPT0WU
YAPCMmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTJ6LkK1OlQh|ryPMVjTRW5ITVJ?
SNU-C2BNH3y[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvpT21KSzVyPUK4MlI6PjRizszNMl\qV2FPT0WU
RCC10RGBNEjvXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zOemlEPTB;MkiuOVQyPyEQvF2=M4LPW3NCVkeHUh?=
ES7MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJ7LkG0OlUh|ryPMXrTRW5ITVJ?
PANC-03-27MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWr0[o5yUUN3ME2yPU41PDRizszNMkXRV2FPT0WU
ES6MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnOxTWM2OD1{OT64NVU4KM7:TR?=M{HqW3NCVkeHUh?=
HT-1197MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDZb3VKSzVyPUOwMlA2QThizszNNWLBNJQ{W0GQR1XS
ZR-75-30MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXITWM2OD1|MD6yN|g{KM7:TR?=M1\sSnNCVkeHUh?=
DBNIP0VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTNyLkS5OFIh|ryPM4fl[HNCVkeHUh?=
OCI-AML2NG\D[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\4[mlEPTB;M{GuNFY6KM7:TR?=MYXTRW5ITVJ?
NCI-H2170MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHnTWM2OD1|MT64OVE3KM7:TR?=NHXKeXJUSU6JRWK=
IST-MES1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf6TWM2OD1|Mj6yPFk4KM7:TR?=Mn:2V2FPT0WU
769-PNWnLTJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTN{LkO2OFEh|ryPMlzVV2FPT0WU
COR-L23NHLxPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;oe2lEPTB;M{KuPVA4OyEQvF2=NXnDcnVPW0GQR1XS
SW626MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17M[WlEPTB;M{OuNVc4PiEQvF2=M3L6dHNCVkeHUh?=
LU-139NYTRepQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmm4TWM2OD1|Mz62OlA2KM7:TR?=NVLEZmhzW0GQR1XS
HT-144M4rZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvQTWM2OD1|Mz64OlMh|ryPMX7TRW5ITVJ?
CaR-1MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILlbmFKSzVyPUOzMlk5OjJizszNMXnTRW5ITVJ?
OE33NIrmWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zXPGlEPTB;M{SuNlg2PSEQvF2=NYXZOmVZW0GQR1XS
COLO-800MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\aRo42UUN3ME2zOE4{PjR5IN88US=>MmmxV2FPT0WU
NB14MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TTS2lEPTB;M{SuOFY5PCEQvF2=NHGwZphUSU6JRWK=
KURAMOCHINXviNYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjLdWZHUUN3ME2zOk4yOTl6IN88US=>NV3IU2tkW0GQR1XS
SW48NXiwbIw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXT1PWRwUUN3ME2zOk4zPDd2IN88US=>MmfvV2FPT0WU
DaoyMn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TZZmlEPTB;M{[uOlU{QCEQvF2=M2nZS3NCVkeHUh?=
TGBC24TKBNVXxfYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\vNGlEPTB;M{[uOlch|ryPNEPBWpVUSU6JRWK=
DU-4475M1;HcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILD[XdKSzVyPUO2MlkxOzNizszNNFPLVWNUSU6JRWK=
SW1417MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTN6LkC1OVIh|ryPNGOyRW9USU6JRWK=
EFO-21MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTiWJQ4UUN3ME2zPE46OzR7IN88US=>MVLTRW5ITVJ?
MG-63NHXqcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTjTWM2OD1|OT6zOFI1KM7:TR?=NVTzcVZnW0GQR1XS
LC-2-adNV\VWG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTN7LkW1NVIh|ryPNHjaSWVUSU6JRWK=
NOMO-1NFPQOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTXZWF3UUN3ME2zPU45Ojd2IN88US=>NXnWcYdvW0GQR1XS
COLO-741M2TCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TNb2lEPTB;NECuNVMxPCEQvF2=MnH1V2FPT0WU
BxPC-3NIDIZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRyLkW2PFYh|ryPMWfTRW5ITVJ?
HSC-2NGPaSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTRyLkmxNVMh|ryPMUDTRW5ITVJ?
UMC-11M{n0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDkU2EzUUN3ME20NU4zPjNizszNMkXNV2FPT0WU
HCC1937M1nuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TVUWlEPTB;NEKuO|g1OyEQvF2=NIWyepFUSU6JRWK=
Calu-6NGjGZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXQbGJKSzVyPUSzMlI{QDJizszNNIPKV|BUSU6JRWK=
NCI-H1573M1ntZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NES3RVZKSzVyPUSzMlM1PzdizszNNXGxeIdVW0GQR1XS
SK-N-ASMkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX31U2F7UUN3ME20N{43ODF7IN88US=>M4[yUXNCVkeHUh?=
PSN1M{\UWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWX0OY5WUUN3ME20OU4zPTR6IN88US=>NFzCUFdUSU6JRWK=
TE-11NXiyTotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\Ke2lEPTB;NEWuOFg1OiEQvF2=M17XcnNCVkeHUh?=
NCI-H1155NH3JNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7MSm1xUUN3ME20OU45QTZ5IN88US=>NVLSU|dbW0GQR1XS
KM12NGXXco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDqRXl1UUN3ME20OU46ODd4IN88US=>Mnj6V2FPT0WU
RO82-W-1NVm5[IdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\iTYE6UUN3ME20Ok46QDJ{IN88US=>NHmwcXdUSU6JRWK=
SW1573MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVO3fG5JUUN3ME20O{4{PzN4IN88US=>MnO0V2FPT0WU
CAKI-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPjTWM2OD12OD6yPFQ2KM7:TR?=MWTTRW5ITVJ?
U-118-MGM3O4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrJTWM2OD12OD6zO|AzKM7:TR?=NWCyZ5ZDW0GQR1XS
KYSE-520Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rQNWlEPTB;NEiuOFAyPiEQvF2=M{f0eHNCVkeHUh?=
HT55NYnLOnJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljDTWM2OD12OT6xOFc1KM7:TR?=NHnIW2lUSU6JRWK=
ChaGo-K-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP0emFKSzVyPUS5MlQ4QTNizszNMmnsV2FPT0WU
IA-LMMmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HYVmlEPTB;NUSuOlMzOiEQvF2=M2nyZXNCVkeHUh?=
UACC-62MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrWSGFKSzVyPUW1MlExPDZizszNNYD0OllSW0GQR1XS
MKN7NIDzTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTV4LkCyPFUh|ryPM{nwZ3NCVkeHUh?=
HPAF-IIMmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTV4LkSwO|Mh|ryPNXXiUG1yW0GQR1XS
NTERA-S-cl-D1MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTV5Lke3PEDPxE1?M3HifXNCVkeHUh?=
FTC-133MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPFTWM2OD13OD6wPVY6KM7:TR?=NVXSPHRxW0GQR1XS
MHH-ES-1NH3uN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;PTWM2OD13OD60PFE1KM7:TR?=NXLGeJlEW0GQR1XS
JVM-2NFXlXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDINVloUUN3ME21PE46PTB4IN88US=>MWPTRW5ITVJ?
TCCSUPNGjUOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XXNGlEPTB;NUmuOVI4QSEQvF2=NGm2NJlUSU6JRWK=
COLO-824MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\kUoRQUUN3ME22NE4xPzF7IN88US=>MWrTRW5ITVJ?
647-VNYmzcHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2D3emlEPTB;NkCuNVM1PyEQvF2=MW\TRW5ITVJ?
HD-MY-ZNFHENVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LaXWlEPTB;NkCuOVI6PCEQvF2=MYnTRW5ITVJ?
LS-411NNVjQb2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTZzLkO5NFMh|ryPMXrTRW5ITVJ?
NCI-H596NVvmbWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2izWmlEPTB;NkKuO|Q6PiEQvF2=MU\TRW5ITVJ?
C-33-ANUP4RWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fq[2lEPTB;NkSuNFk2PyEQvF2=MXjTRW5ITVJ?
BHYMoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHZdFNKSzVyPU[0MlEzPDVizszNM{O5ZXNCVkeHUh?=
KGNMmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTZ2LkW1NVQh|ryPM1TzUnNCVkeHUh?=
NCI-H1092NYrsc2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXXTWM2OD14NT6wNFk2KM7:TR?=NXHsfGI4W0GQR1XS
MZ1-PCM33KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELBdHBKSzVyPU[1MlU3PDlizszNMXnTRW5ITVJ?
LB831-BLCNVrmN3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TIeGlEPTB;NkWuPFQ5OSEQvF2=M4rLVXNCVkeHUh?=
SW620NXnt[mcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvlTWM2OD14Nj6yNFM6KM7:TR?=M3v3WnNCVkeHUh?=
HuO-3N1MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPwTWM2OD14OD6zNlM5KM7:TR?=MX\TRW5ITVJ?
SK-HEP-1NXXzVJhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\pR5lKSzVyPU[5Mlk1QDZizszNMWfTRW5ITVJ?
LCLC-103HMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTdyLk[3NFUh|ryPNYT5c5pPW0GQR1XS
KYSE-70MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfsXmhIUUN3ME23NE44QDN3IN88US=>NX3NWmNsW0GQR1XS
MewoNWf2UlM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTdzLkWwOUDPxE1?NWPDPIVCW0GQR1XS
COLO-668MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT5TWM2OD15MT64OFUyKM7:TR?=MVLTRW5ITVJ?
NCI-H522NELBTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTDTWM2OD15Mj6zOFE{KM7:TR?=NY\COmVFW0GQR1XS
NCI-H1437NY\Y[4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rJcWlEPTB;N{SuOFA1QCEQvF2=NWHXPXF{W0GQR1XS
U-266NVPqXYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml20TWM2OD15NT60OVE3KM7:TR?=NIe1ZZZUSU6JRWK=
MC116MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;0TWM2OD15NT61O|A5KM7:TR?=MX7TRW5ITVJ?
PANC-10-05M3LkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDEd|g2UUN3ME23O{41OjR|IN88US=>M3y3SHNCVkeHUh?=
KYSE-180MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:2WHRKSzVyPUe3MlU1PTRizszNM3X4dHNCVkeHUh?=
JARMkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3GTmx[UUN3ME23PU4xPTR4IN88US=>NGDwS|NUSU6JRWK=
CAL-62MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvzZVBKSzVyPUiwMlA6PSEQvF2=NFnlco1USU6JRWK=
A3-KAWMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnqfWVKSzVyPUiwMlIyPTRizszNMXrTRW5ITVJ?
PANC-08-13MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRThzLkG3Olgh|ryPMWfTRW5ITVJ?
HSC-3NXTvWIplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;jTWM2OD16Mz6zNFcyKM7:TR?=NH;nRmZUSU6JRWK=
HTC-C3NYjoWHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fNSWlEPTB;OEOuOFcxOiEQvF2=MmmyV2FPT0WU
KY821NHzHbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13PTGlEPTB;OESuNFg6OiEQvF2=MYjTRW5ITVJ?
DoTc2-4510MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nVRmlEPTB;OESuNlE5PSEQvF2=M4ftdHNCVkeHUh?=
NCI-H1581Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTh3LkS2OFEh|ryPMXTTRW5ITVJ?
KARPAS-299NGS0To5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jmdmlEPTB;OE[uNVk4PyEQvF2=MoLIV2FPT0WU
IST-MEL1NWK4ZoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nJNWlEPTB;OE[uPFg4OiEQvF2=NIrFbIVUSU6JRWK=
KP-N-YSNE\sToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\uVpNKSzVyPUi5MlkxOjhizszNNVTUV|I2W0GQR1XS
KYSE-410NU\uc45nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnRcIVKSzVyPUmxMlQxPDJizszNNHvrR3VUSU6JRWK=
TE-10NWXoSGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTlzLkW2NVEh|ryPNEj2c4JUSU6JRWK=
SK-MEL-1NUfpbHVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzsTHlKSzVyPUmyMlkyODZizszNM2KyeHNCVkeHUh?=
COLO-792NX[yTnFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLsVFZKSzVyPUm1MlI2PjRizszNMW\TRW5ITVJ?
SCHNH;NZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW1TWM2OD17Nj6zPFc4KM7:TR?=M1vIOXNCVkeHUh?=
NCI-H1792M{j4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rCU2lEPTB;OU[uPFk6OiEQvF2=NYLtRmJsW0GQR1XS
NCI-H2029MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HPd2lEPTB;OU[uPVU3PiEQvF2=M3LhbHNCVkeHUh?=
SW684NF3nWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTl6Lk[2OVQh|ryPM3KycHNCVkeHUh?=
NCI-H209MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFyMD6xNlEh|ryPNVGwcmwzW0GQR1XS
HLENXXpNG1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\mfYZEUUN3ME2xNFUvOjh{IN88US=>MmPqV2FPT0WU
GOTOMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTVS2V[UUN3ME2xNFcvPzd5IN88US=>NXXXbFJmW0GQR1XS
NCI-H1793MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkSwTWM2OD1zMEmuNlgh|ryPNYjxSI9rW0GQR1XS
D-392MGNIXiN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkD0TWM2OD1zMUeuN|k5KM7:TR?=MX7TRW5ITVJ?
SW1990NHK3UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoO2TWM2OD1zMkCuPVUyKM7:TR?=MofxV2FPT0WU
ML-2MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTaTWM2OD1zMkGuOlc3KM7:TR?=MXPTRW5ITVJ?
NCI-H2452NFj6[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M122TmlEPTB;MUKyMlIyKM7:TR?=MUDTRW5ITVJ?
SK-MEL-30NUTvdW14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1L0NGlEPTB;MUKzMlI1PCEQvF2=M1vTeXNCVkeHUh?=
SN12CNVi5PWFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGCyWVhKSzVyPUGyOE4yPzZizszNNVT4VXNGW0GQR1XS
NCI-H1770Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfWTWM2OD1zMkWuOVE1KM7:TR?=NInHUFZUSU6JRWK=
SF268M1nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF{Nj6xOVgh|ryPMXjTRW5ITVJ?
BALL-1NGfqcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzHZldHUUN3ME2xNlYvOjNizszNMXXTRW5ITVJ?
COLO-679M1TqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYT1[ZJqUUN3ME2xNlYvPzV|IN88US=>M2iyXHNCVkeHUh?=
A2780MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\qTWM2OD1zMkiuPVg5KM7:TR?=MVvTRW5ITVJ?
NCI-H1651MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTF|MT6yOFMh|ryPNXvydpJJW0GQR1XS
NCI-H2087NGeybplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfHNnQyUUN3ME2xN|EvPDh|IN88US=>NHLuOYdUSU6JRWK=
U-87-MGNH3UOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPHTWM2OD1zM{OuOlA1KM7:TR?=NUTzfYZ{W0GQR1XS
LB2518-MELNV73fI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfD[ndEUUN3ME2xN|UvQTl|IN88US=>MljKV2FPT0WU
HCT-116M17kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF|Nz6yNVch|ryPMXrTRW5ITVJ?
Ca9-22NHfvRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTF|OT64N|Mh|ryPMUTTRW5ITVJ?
COR-L88MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjldYpUUUN3ME2xOFIvOTRizszNM{HxNHNCVkeHUh?=
CP50-MEL-BMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTF2ND61NFEh|ryPNX;QTYRJW0GQR1XS
OVCAR-8MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrNTWM2OD1zNEWuOlM3KM7:TR?=MXHTRW5ITVJ?
SK-MEL-3NIOzemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XP[2lEPTB;MUS3Mlg4QCEQvF2=NIXl[lVUSU6JRWK=
GT3TKBNEK1R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHXWo1lUUN3ME2xOFkvQTJ6IN88US=>MX\TRW5ITVJ?
KYSE-450NH;oTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LEOmlEPTB;MUWxMlU{QSEQvF2=MV3TRW5ITVJ?
CAPAN-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILJT5NKSzVyPUG1N{4xPjRizszNNVrXfoQ{W0GQR1XS
BENMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnycHU5UUN3ME2xOVMvQTJ6IN88US=>MYXTRW5ITVJ?
NCI-H1304M2\xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXxNJZKSzVyPUG1OE43QTRizszNM4jafXNCVkeHUh?=
KU812M1TqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4O4PWlEPTB;MUW4MlY4PCEQvF2=MoTIV2FPT0WU
Capan-2NITPfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4T1dGlEPTB;MU[wMlU2OyEQvF2=M1vhe3NCVkeHUh?=
A673MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi5TWM2OD1zNkGuO|A2KM7:TR?=M{fsSXNCVkeHUh?=
SASMkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTF4Mj62O|gh|ryPMXTTRW5ITVJ?
NYM{DqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITRR2xKSzVyPUG2OU4{OTRizszNNU\YV5JwW0GQR1XS
HCE-4NWXVVHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV62U2RkUUN3ME2xOlYvQDR3IN88US=>M4jHVnNCVkeHUh?=
MDA-MB-231MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUC2SoVVUUN3ME2xO|cvPTB|IN88US=>MkDSV2FPT0WU
no-10M322Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF5OD6xN|Qh|ryPMYLTRW5ITVJ?
MZ7-melNGX0cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2CyT2lEPTB;MUe4MlQ3PyEQvF2=MXXTRW5ITVJ?
NCI-H82M{nQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF6MD6xOlUh|ryPM2PvNHNCVkeHUh?=
CAL-72MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTF6NT6wOVQh|ryPM{nGbHNCVkeHUh?=
NCI-SNU-5MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHT[plKSzVyPUG4Ok45PCEQvF2=NUXON3I5W0GQR1XS
OVCAR-4MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTF6OD6zN|Mh|ryPMXnTRW5ITVJ?
SCC-9M2jmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF7MTFOwG0>MU\TRW5ITVJ?
KYSE-150NHvxXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjlTWM2OD1zOUGuPFg5KM7:TR?=M{PBenNCVkeHUh?=
HT-29NFTpV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLuUHFwUUN3ME2yNFEvOjF{IN88US=>NGrv[llUSU6JRWK=
COLO-678M3e5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7yeZBKSzVyPUKwNU41PSEQvF2=MYHTRW5ITVJ?
NCI-H650MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\Z[WlEPTB;MkCyMlExOyEQvF2=MnzOV2FPT0WU
HuCCT1NXrYN|JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPaTWM2OD1{MESuNlA5KM7:TR?=Mn:xV2FPT0WU
SW1116NYW5UJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJyNz6wO|ch|ryPMYLTRW5ITVJ?
DBTRG-05MGNIm2WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDJV3ZRUUN3ME2yNFcvQTB7IN88US=>NVTXS5dxW0GQR1XS
SW982M1;DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDNZXJbUUN3ME2yNFcvQTR6IN88US=>MoThV2FPT0WU
RCM-1NXP5THRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVyxco1YUUN3ME2yNVQvPzZ{IN88US=>MVfTRW5ITVJ?
COLO-320-HSRNWHwOXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUK4VFF{UUN3ME2yNVYvOTJ3IN88US=>MomzV2FPT0WU
KNS-42MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTJzNj61O|Qh|ryPNVTGboFpW0GQR1XS
C2BBe1MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJ|MT65NFUh|ryPMmHRV2FPT0WU
CCRF-CEMM4LDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\KdWlEPTB;MkSzMlc6PSEQvF2=MWXTRW5ITVJ?
SH-4NYPoSm04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ2Nj6wPUDPxE1?MkL3V2FPT0WU
LS-1034M3:xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\WTWM2OD1{NE[uNlY3KM7:TR?=Ml;UV2FPT0WU
NCI-H2347NUC5bZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3tZmxVUUN3ME2yOFcvPzF|IN88US=>MVfTRW5ITVJ?
RPMI-8866NV3ERXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ2OT6yO{DPxE1?NHLuTpVUSU6JRWK=
GAKMljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTJ3Mz6wNFIh|ryPNVG0dWtPW0GQR1XS
NB6NHjzOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjRT|lKSzVyPUK3NE4yKM7:TR?=M{Hrc3NCVkeHUh?=
COLO-680NMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjSOY54UUN3ME2yO|IvPTJ5IN88US=>NFHJdWpUSU6JRWK=
RERF-LC-MSNFHLRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTxd2lEUUN3ME2yO|YvODB5IN88US=>MnPOV2FPT0WU
TGBC11TKBMnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHRe4RKSzVyPUK3PE4yPzhizszNNVThWmJSW0GQR1XS
C8166MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJ5OD61NFYh|ryPMWDTRW5ITVJ?
HDLM-2Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33aTGlEPTB;Mkm0MlQxQSEQvF2=NIGyfWJUSU6JRWK=
IGR-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJ7NT62OVkh|ryPM3\wUnNCVkeHUh?=
FADUM124RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rYbGlEPTB;Mkm3MlUyKM7:TR?=NXrURVFbW0GQR1XS
L-428NI\sPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJ7Nz62NVYh|ryPM4HMT3NCVkeHUh?=
LU-65M{HRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn[1TWM2OD1|MESuN|Ih|ryPM1O3UHNCVkeHUh?=
HELMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDUTWM2OD1|MEmuPVg{KM7:TR?=Mn;zV2FPT0WU
NCI-H810MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTNzMD61O{DPxE1?MX3TRW5ITVJ?
C3AMke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTNzMT64NFIh|ryPNYS2T3lIW0GQR1XS
NCI-H630M4P2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PHdWlEPTB;M{OyMlI6PCEQvF2=MVnTRW5ITVJ?
KP-N-YNNFTYXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rlSWlEPTB;M{SxMlEzOyEQvF2=NVnmWGxTW0GQR1XS
MOLT-13MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvqTWM2OD1|NEKuN|I3KM7:TR?=MXTTRW5ITVJ?
NCI-H1993NV\idYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4e2dWlEPTB;M{SyMlM3PSEQvF2=MUjTRW5ITVJ?
BE-13NFXjSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTN2ND6xOlch|ryPNGLjeIhUSU6JRWK=
IST-SL1NUTuSVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTN2Nz60NFEh|ryPMV7TRW5ITVJ?
TE-9NYmyXWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXSw[Y55UUN3ME2zOlMvPTh7IN88US=>NGK4VIdUSU6JRWK=
LU-135NEflTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTN4Nz6wN|Uh|ryPMY\TRW5ITVJ?
T84MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{SxWWlEPTB;M{e0MlcyOiEQvF2=M{HUb3NCVkeHUh?=
K-562M1\CbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfmTIN5UUN3ME2zPFMvOzZizszNNHvK[nVUSU6JRWK=
SBC-5MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTN6Nj65PFUh|ryPNUn0T4VOW0GQR1XS
NB17NUfKTmVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLMTWM2OD1|OUKuOVk3KM7:TR?=MVvTRW5ITVJ?
NCI-H2052NVSzcY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr1TWM2OD1|OUiuOFczKM7:TR?=NYHueY5iW0GQR1XS
HCC38Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknzTWM2OD12MEGuOVk{KM7:TR?=NHH1foRUSU6JRWK=
NCI-H69M{fIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;LW|dKSzVyPUS0NU4xQDNizszNNXLJcoo6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.

Protocol(Only for Reference)

Kinase Assay: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

Cell Assay: [2]

Cell lines A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
Concentrations 0, 0.3, 1 and 3 μM
Incubation Time 72 or 96 hours
Method MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

Animal Study: [2]

Animal Models SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
Formulation Formulated in 30% Captisol
Dosages 120 mg/kg
Administration Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.

[2] Hirai H, et al. Mol Cancer Therapy, 2010, 9(7), 1956-1967.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent  ...more Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|St  ...more Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adu  ...more Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|  ...more Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

view more

Chemical Information

Download MK-2206 2HCl SDF
Molecular Weight (MW) 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

Customer Product Validation (18)


Click to enlarge
Rating
Source Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines Ser78 cells
Concentrations 5 µM
Incubation Time 1 h
Results Two selective AKT inhibitors MK-2206 and GDC-0068, both significantly reduced MKK4 phosphorylation on Ser78 in axons after injury.

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck
Method 3D migration model
Cell Lines WT or Rap1b-/- neutrophil
Concentrations 2 uM
Incubation Time
Results MK-2206 treatment completely reversed elevated TEM across mouse endothelial cells of Rap1b-/- neutrophils to WT levels (A). It reduced ECM degradation of Rap1b -/- neutrophils, and inhibited their multiple protrusions (B and C). Furthermore, almost all Rap1b -/- cells treated with MK-2206 were found at the endothelial cell junctions (D).

Click to enlarge
Rating
Source Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines HUVECs
Concentrations 1 uM
Incubation Time 8 h
Results Because YAP is also a known substrate of Akt21, we examined whether blockade of the Akt pathway affects YAP phosphorylation. Both Ly294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and MK-2206, an allosteric inhibitor of Akt, suppressed cell contact-mediated YAP phosphorylation.

Click to enlarge
Rating
Source Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck
Method Immunoblotting
Cell Lines CXCR4S338X-expressing BCWM.1 cells
Concentrations 0.5 uM
Incubation Time 6 h
Results As AKT and ERK, but not BTK, show continued SDF-1a-triggered activation in CXCR4S338X-expressing WM cells treated with ibrutinib, we next sought to clarify if AKT and ERK contributed to the enhanced survival of these cells. It therefore treated SDF-1acultured CXCR4S338X BCWM.1 cells with either AKT- (MK-2206 and AZD-5363) or MEK- (AS-703026, AZD-6244 and UO126) specific inhibitors with and without ibrutinib (0.5 uM) for 6 h so as to clarify the contribution of AKT and ERK to ibrutinib resistance. The inhibitory activity of MK-2206, as well as AS-703026, AZD-6244 and UO126 was confirmed by western blot analysis for pAKT (S473) and pERK (T202/Y204), respectively.

Click to enlarge
Rating
Source Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

Product Use Citation (169)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Recently Viewed Items

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us